Lilly and Roche's antibodies fail late-phase Alzheimer's test

Lilly and Roche's antibodies fail late-phase Alzheimer's test

Source: 
Fierce Biotech
snippet: 

Anti-amyloid beta antibodies in development at Eli Lilly and Roche have failed to improve outcomes in a phase 2/3 Alzheimer’s disease trial. Despite the setback, Roche is continuing two phase 3 trials of its asset in a broader population of Alzheimer’s patients.